Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · IEX Real-Time Price · USD

0.970

+0.045 (4.90%)

At close: Jul 19, 2024, 4:00 PM

0.880

-0.090 (-9.28%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Xilio Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	25.74	27	29.95	23.86	10.65	4.77
Research & Development	46.41	52.14	59.2	51.19	43.91	14.26
Other Operating Expenses	0.95	0	0	0	0	0
Operating Expenses	73.09	79.13	89.15	75.04	54.56	19.03
Operating Income	-73.09	-79.13	-89.15	-75.04	-54.56	-19.03
Other Expense / Income	-2.13	-2.73	-0.93	0.76	0.66	-1.72
Pretax Income	-70.96	-76.4	-88.22	-75.8	-55.22	-17.31
Net Income	-70.96	-76.4	-88.22	-75.8	-55.22	-17.31
Shares Outstanding (Basic)	28	27	27	6	1	4
Shares Outstanding (Diluted)	28	27	27	6	1	4
Shares Change	1.75%	0.38%	388.59%	970.34%	-86.53%	-
EPS (Basic)	-2.57	-2.78	-3.22	-13.52	-105.42	-4.45
EPS (Diluted)	-2.57	-2.78	-3.22	-13.52	-105.42	-4.45
Free Cash Flow	-54.19	-69.11	-77.59	-81.85	-38.28	-18.56
Free Cash Flow Per Share	-1.94	-2.51	-2.83	-14.60	-73.08	-4.77
EBITDA	-69.12	-74.5	-86.38	-74.3	-54.15	-17.07
Depreciation & Amortization	1.84	1.9	1.85	1.5	1.07	0.24
EBIT	-70.96	-76.4	-88.22	-75.8	-55.22	-17.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).